Search Results

Results for "/clinical/?page=1"

Nivolumab/Ipilimumab Improves OS in Unresectable Malignant Pleural Mesothelioma

August 10, 2020

Nivolumab in combination with ipilimumab significantly improved overall survival (OS) in treatment-naïve patients with unresectable malignant pleural mesothelioma (MPM) who were treated in the phase 3 CheckMate 743 clinical trial.

CS1001 Plus Chemotherapy Prolongs Progression-Free Survival in Stage IV NSCLC

August 07, 2020

The combination of CS1001 and chemotherapy led to an improvement in progression-free survival among patients with stage IV squamous and non-squamous non–small cell lung cancer, according to data from the phase 3 CS1001-302 clinical trial assessed by an Independent Data Monitoring Committee, achieving the study’s primary end point.

OPTIMA Trial Will Continue to Follow Patients With HCC Treated With ThermoDox Combo

August 05, 2020

Patients with hepatocellular carcinoma, or primary liver cancer, treated with ThermoDox plus radiofrequency ablation in the phase 3 OPTIMA clinical trial will continue to be followed for overall survival.

Tisagenlecleucel Demonstrates Favorable Complete Response Rate, Meets Phase II Primary End Point

August 04, 2020

Tisagenlecleucel, a chimeric antigen receptor T-cell therapy, showed evidence of clinical benefit for patients with relapsed or refractory follicular lymphoma, in terms of complete response rate, meeting the primary end point of the phase 2 ELARA clinical trial.

Salvage Blinatumomab Therapy Generates Durable Responses in Relapsed/Refractory DLBCL

August 03, 2020

Blinatumomab as salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma may induce durable complete responses and a survival benefit, according to a pooled analysis of 3 clinical trials.

Pembrolizumab Demonstrated Complete Responses in Non-Muscle Invasive Bladder Cancer

August 03, 2020

The immune checkpoint inhibitor pembrolizumab appeared well-tolerated with encouraging antitumor activity as treatment of patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin, according to the updated follow-up from the phase 2 KEYNOTE-057 clinical trial.